Phase 2 Oesophageal Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 years or older.
• People who have been diagnosed (confirmed by laboratory testing of tissue or cells) with relapsed, locally advanced, or metastatic esophageal cancer, or other advanced solid tumours.
• People who have at least one tumour that can be measured using standard imaging criteria (note: the oesophagus itself cannot count as a measurable lesion).
• People who are willing to provide tumour tissue samples (either freshly collected or previously stored) and blood samples.
• People with a general health and activity level rated as 0 or 1 on a standard medical scale, meaning they are either fully active or have only minor limitations in physical activity.
• People with a life expectancy of more than 12 weeks as estimated by their doctor.
• People who agree to use medically accepted contraception throughout the study.
• Women who are confirmed not to be pregnant at screening, or who are confirmed to have no possibility of becoming pregnant.
• People who have signed and dated the trial's informed consent form.

Who may not be able to join:

• People who have previously received or are currently receiving treatment targeting a protein called B7-H3, or who have received certain chemotherapy or other anticancer drugs within 14 days before the first planned dose, or a monoclonal antibody treatment within 28 days before the first planned dose.
• People who have had localised radiation therapy for symptom relief within 2 weeks before the first dose, radiation to more than 30% of their bone marrow, or large-scale radiotherapy within 4 weeks before the first planned dose.
• People who have had major surgery within 4 weeks before the first planned dose.
• People who have had, or currently have, another separate cancer diagnosis.
• People whose oesophageal tumour has grown significantly into nearby structures such as the aorta or airway, as this may increase the risk of bleeding or abnormal openings (fistula).
• People whose bone marrow, liver, kidneys, or other organs are not functioning adequately (confirm with trial site for specific measurements).
• People with signs of heart or blood vessel problems (confirm with trial site for specific details).
• People with severe or poorly controlled ongoing illnesses.
• People who have had signs of bleeding from the digestive system or other internal areas within 1 month before the first planned dose.
• People who have had a severe infection within 4 weeks before the first planned dose.
• People with known active infectious diseases such as hepatitis B or hepatitis C.
• People with a history of nerve damage conditions or mental health disorders.
• Women who are pregnant or breastfeeding.
• People who have had a severe allergic reaction or serious reaction to drugs similar to the study drug (HS-20093) or any of its ingredients.
• People who have had a vaccination or any allergic reaction of any level within 4 weeks before the first planned dose.
• People who, in the opinion of the trial doctor, are unlikely to follow the study's procedures and requirements.
• People who have any other disease or condition that the trial doctor believes could affect their safety or interfere with study results.

Important: Always verify eligibility with the trial site directly before applying.